1Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive maker of response to breast cancer therapy [J]. Breast Cancer Res Treat, 1998, 52(1-3): 65-77.
2Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts [ J] .Nature, 1981,290( 5803 ): 261-264.
3Schechter Al,Sten DF, Vaidyanathan L,et al. The neu oncogene: an erbB-related gened encoding a 185, 000-Mr tumour antigen [ J]. Nature.1984,312(5994) :513-516 .
4Miller JL. Progress in breast cancer treatment: prevention, new therapyes come to forefront[J]. Am J Health Syat Pharm, 1998, 55(22): 2326-2330.
5Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu recaptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells[J].Oncogene, 1994, 9(7): 1829-1838.
6Baselga J, Norton L, Albanell J, et al. Recombinant humanized antiHER2 ntibody (Herceptin) enhances the antihumor activcity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts [J]. Cancer Res, 1998, 58(13): 2825-2831.
7Pegram MD, Hsn S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chem. otherapeutic agents used for treatment of human breast cancers [J], Oncogene, 1999, 18(13): 2241-2251.
8Pegram MD, Baly D, Wirth C, et al.Antibody-dependent cell mediated cytotoxicity in breast cancer patients in phase Ⅲ clinical trials of a humanized anti-HER2 antibody[ J]. Proc Am Assoc Cancer Res, 1997,38:602.
3Scott LJ, Keam SJ. Letrozole: in postmenopausal hormone- responsive early stage breast cancer[J]. Drugs, 2006, 66(3):353.362.
4Lohrisch C,Piccart M.HER2Jneu as a predictive factor in breast cancer[J].Clin Breast Cancer:2001,2(2): 129-135.
5Gianni L,Dafifi U,Gelber RD,et al.Trealment with tmsmztm: for lyear after adjuvant chemotherapy in patients with HER2- positive early breast cancet:a 4-year follow-up of a randomized conlrolled Irial[J]. Lancet Oncol.2011,12(3):236-244.
6Perez EA,Romond EH, Suman VJ,et al.Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast canc:joint analysis of data from NCCTG N9831 and NSABP B-31 [J].J Clin Oncol,2011,29(25):3366- 3373.
